Paclitaxel as second-line chemotherapy in patients with gemcitabine-refractory pancreatic cancer: a retrospective study
- 1 April 2011
- journal article
- research article
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 16 (5) , 539-545
Abstract
We evaluated the efficacy and feasibility of paclitaxel in patients with gemcitabine-refractory pancreatic cancer. We also evaluated the correlation between tumor marker decline and response rate. Thirty patients histologically diagnosed with pancreatic cancer who had undergone paclitaxel treatment as salvage chemotherapy were retrospectively analyzed. Paclitaxel treatment was performed with 80 mg/(m2 week) for 3 weeks followed by 1 week rest, and this was continued until failure. Tumor marker response was evaluated by measuring levels of carbohydrate antigen 19-9, carcinoembryonic antigen, and DUPAN-2 monthly. In total, 272 weekly paclitaxel treatments were performed. The median number of treatments per patient was 8 (range 1–22). The median overall survival from the start of paclitaxel treatment was 6.7 months (range 1.2–18.8). The response rate was 10% (3/30 patients) and the disease control rate was 46.7% (14/30 patients). Although grade 3 and 4 hematological and non-hematological toxicities were seen in 7 and 6 patients, respectively, adverse events were managed by conservative treatment. We found a significant correlation between the disease control rate and tumor marker decline within 2 months of paclitaxel treatment (P = 0.01). Patients with tumor marker decline tended to survive longer. Weekly administration of paclitaxel in patients with gemcitabine-refractory pancreatic cancer seems to be well tolerated and can be effective. Paclitaxel treatment should be considered as salvage chemotherapy after gemcitabine failure in patients with good performance status.Keywords
This publication has 29 references indexed in Scilit:
- Cancer Incidence and Incidence Rates in Japan in 2003: Based on Data from 13 Population-based Cancer Registries in the Monitoring of Cancer Incidence in Japan (MCIJ) ProjectJapanese Journal of Clinical Oncology, 2009
- A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic CancerBritish Journal of Cancer, 2009
- Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology GroupJournal of Clinical Oncology, 2009
- Significantly Longer Progression-Free Survival With nab-Paclitaxel Compared With Docetaxel As First-Line Therapy for Metastatic Breast CancerJournal of Clinical Oncology, 2009
- Apparent beneficial effects by nab-paclitaxel in the treatment of refractory metastatic ovarian carcinomaAnti-Cancer Drugs, 2009
- Phase I/II Trial of Weekly Intravenous 130-nm Albumin-Bound Paclitaxel As Initial Chemotherapy in Patients With Stage IV Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2008
- Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiationCancer, 2006
- Albumin-Bound PaclitaxelDrugs, 2006
- Are Serial CA 19-9 Kinetics Helpful in Predicting Survival in Patients with Advanced or Metastatic Pancreatic Cancer Treated with Gemcitabine and Cisplatin?Oncology Research and Treatment, 2003
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000